AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04709484
Drug: Palpation-guided steroid injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the palpation-guided group, the most painful point will be found by palpation on the calcaneus bone and steroid injection will be made to that part. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.
Trial: NCT04796688
Drug: Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells
RxNorm normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fludarabine 30 mg/kg on day -5, -4, and -3; cyclophosphamide 300 mg/kg on day -5, -4, and -3; CAR-NK-CD19 Cells on day 0.
Trial: NCT04947631
Drug: DKF-313 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily for 48 weeks
Trial: NCT05118984
Drug: Azithromycin capsule (Zithromax, Pfizer) (250 mg)
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin, a second generation macrolide, broad-spectrum antibacterial that stops bacterial growth by inhibiting protein synthesis and translation, treating bacterial infections Azithromycin has additional immunomodulatory effects and has been used in chronic respiratory inflammatory diseases for this purpose. .Azithromycin has been beneficial in the treatment of influenza and Middle East respiratory syndrome coronavirus (MERS-CoV) and recently has shown to be effective against severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) when used in combination with hydroxychloroquine or chloroquine.
Trial: NCT05118984
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A treatment that has no active properties
Trial: NCT04924036
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for this study are cloths that look like the qbrexza cloths but do not have any active ingredient.
Trial: NCT05180318
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline
Trial: NCT05632549
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 (n=22) which will receive traditional therapy plus placebo capsule twice daily for 3 months.
Trial: NCT05632549
Drug: L-Carnitine 500Mg Oral Tablet
RxNorm normalized name: L-Carnitine 500mg Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 (n=22) which will receive traditional therapy plus L-carnitine capsules (500 mg twice daily) for 3 months.
Trial: NCT05632549
Drug: Biotin Capsules
RxNorm normalized name: Biotin Capsules
DrugBank: Biotin (DB00121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group 3 (n=22) which will receive traditional therapy plus Biotin capsules (5 mg twice daily) for 3 months.
Trial: NCT05450887
Drug: Obeticholic Acid Tablets（OCA）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obeticholic Acid：Once a day (QD) by mouth (PO).
Trial: NCT05450887
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo：Once a day (QD) by mouth (PO).
Trial: NCT05238012
Drug: Xuezhikang Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuezhikang Capsule, 1200mg / day, twice a day, 2 capsules each time, after meals in the morning and evening.
Trial: NCT04914390
Drug: AT regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubin 60mg/㎡ d1 or Epirubicin 75mg/㎡ d1 and Nab-paclitaxel 260mg/㎡ d1 of Cycles 1-6 (Q3W) of the neoadjuvant phase of the study; IV injection.
Trial: NCT05300685
Drug: Standard Buccal Harvest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Our institutions current anesthetic regimen. Comparison group
Trial: NCT05300685
Drug: Basic buccal procedure + Long acting local
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of long-acting local anesthetic to the wound bed following the oral graft harvest.
Trial: NCT04766385
Drug: KHK7791
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT06127355
Drug: 500 mg of ursodeoxycholic acid (UDCA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of 500 mg of ursodeoxycholic acid (UDCA) /day
Trial: NCT06300723
Drug: BRL-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD34 + autologous hematopoietic stem and progenitor cells edited at the BCL11A gene.
Trial: NCT05018806
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Tablet Route of administration: Oral
Trial: NCT04798469
Drug: Testosterone Undecanoate 250 MG/ML
RxNorm normalized name: testosterone undecanoate 250 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration at a dose of 750 mg at baseline, weeks 4, and week 14.
Trial: NCT04798469
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of placebo at baseline, weeks 4, and week 14.
Trial: NCT06149117
Drug: test product (T) azithromycin capsule and reference product (R) azithromycin capsule Sumamed®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take one capsule orally every cycle(T or R)
Trial: NCT04844658
Drug: Strandard of care treatment
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strandard of care treatment for Covid-19 infection
Trial: NCT05420467
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2, d1, q3w × 4 cycles followed by docetaxel
Trial: NCT04969965
Drug: aumolertinib
RxNorm normalized name: aumolertinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EQ143 tablet is an oral solid dosage form manufactured at a strength of 55 mg
Trial: NCT05420467
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2, d1, q2w × 4 cycles followed by nab-paclitaxel
Trial: NCT05420467
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2, d1, q3w × 6 cycles
Trial: NCT05602675
Drug: LY3871801
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05602675
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally.
Trial: NCT06465303
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention is for each subject administered as three 30-minutes infusions of placebo
Trial: NCT05074888
Drug: Prospekta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration.
Trial: NCT05074888
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration.
Trial: NCT05502159
Drug: M-TAPA
RxNorm normalized name: m-phenylenediamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Under aseptic conditions, a high-frequency linear probe will be placed on the costochondral angle in the sagittal plane. Then the probe will be slightly angled deeply to visualize the lower view of the perichondrium. We will perform M-TAPA with total of 40 ml (20 ml for each side) of %0,25 bupivacaine.
Trial: NCT04972227
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablets
Trial: NCT05976503
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04662073
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match camostat administered orally four times daily
Trial: NCT05804630
Drug: Different dental anesthetic agents during wisdom tooth surgery (Orabloc®, Octocaine®, and Xylestesin-A®)
RxNorm normalized name: Sus scrofa tooth preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As mentioned in arm/group descriptions. The amount of dental anesthetic agents used during the surgery will be tailored for patient according to their response, which will not exceed the recommended dosage described in the instruction of the product. The amount of the drug used during the surgery will be recorded.
Trial: NCT06148311
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One matching placebo will be given under the tongue on a thin dissolvable film.
Trial: NCT05986942
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In Group dex, dexmedetomidine infusion will be administered to the patient during the operation. Fentanyl bolus dose will be administered during anesthesia induction in group Fen.
Trial: NCT06052111
Drug: Group F (fentanyl group)
RxNorm normalized name: Stomodine F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (1 μg/kg) was given intravenously slowly over 60 seconds before induction of anesthesia as loading dose followed by continuous infusion at a rate of (1μg/kg/hr) after intubation and was stopped 10 minutes before the end of surgery.
Trial: NCT06052111
Drug: Group D (dexmedetomidine group)
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients received loading dose of dexmedetomidine (1 μg/kg) (Precedex, Abbot Laboratories Inc., Abbot Park, IL, USA) intravenously over 15 minutes before induction of anesthesia followed by continuous infusion at a rate of (0.6 μg/ kg/ hr) after intubation and was stopped 10 minutes before the end of surgery.
Trial: NCT06453603
Drug: corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive pes anserinus corticosteroid injection
Trial: NCT06214052
Drug: VH4524184
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VH4524184 will be administered.
Trial: NCT06214052
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered.
Trial: NCT06511739
Drug: SYHX1901
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYHX1901 tablet
Trial: NCT06511739
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT05630222
Drug: Ibuprofen 800 mg
RxNorm normalized name: ibuprofen 800 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen from Caspian Taamin Company
Trial: NCT05630222
Drug: Ibuprofen 400 mg plus Acetaminophen 1000 mg
RxNorm normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Both from Caspian Taamin Company
Trial: NCT06443658
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients from placebo group will inhale isotonic saline solution 5 minutes before performing the morning ELTGOL technique
Trial: NCT04790812
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single, preemptive oral dose 200mg of celecoxib. A cyclooxygenase-2 (COX-2) selective inhibitor for pain management. A COX-2 selective nonsteroidal anti-inflammatory drug (NSAID).
Trial: NCT04790812
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single, preemptive oral dose 1000mg of acetaminophen. An over-the-counter medication for pain management.
Trial: NCT04790812
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A capsule with no active ingredients designed to mimic the appearance of the acetaminophen capsule to ensure blinding of patients and care providers.
Trial: NCT04829305
Drug: SHR2285
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR2285 is a selective inhibition of human FXIa small molecule compound.
Trial: NCT03285087
Drug: DEX 0.2 μg/kg/h.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEX 0.2 μg/kg/h. The dose will be increased in 0.1 μg/kg/h increments to achieve target Richmond Agitation Sedation Scale (RASS) levels of -2 to zero and with a maximum dose of 1.4 μg/kg/h for 24 hours.
Trial: NCT05250050
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5g bid
Trial: NCT05250050
Drug: Tetracycline
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5g qid
Trial: NCT06268327
Drug: Capecitabine tablets
RxNorm normalized name: Capecitabine Tablets
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients with operable, primary invasive noninflammatory early TNBC of stage I-IIIB and pathologically verified residual cancer cells (no pathological complete response) after neoadjuvant chemotherapy then underwent adjuvant treatment with capecitabine Pt will be followed up every 3 month in first year then every 6 month in the second year then followed up yearly Study will be conducted at Assiut University Hospital with sample size calculation BRACA will be done
Trial: NCT04907149
Drug: GLPG3970 film-coated tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single oral dose of GLPG3970.
Trial: NCT04907149
Drug: [14C]GLPG3970 solution for infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive an i.v. microtracer microdose.
Trial: NCT04907149
Drug: [14]GLPG3970 oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single oral dose \[14C\]GLPG3970.
Trial: NCT05407246
Drug: Hemay005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemay005 60 mg treatment group (group A): hemay005 tablets 60 mg bid were used during the treatment period; Hemay005 75 mg treatment group (group B): hemay005 75 mg bid was used during the treatment period; Placebo group (Group C): placebo (hemay005 tablet simulant) bid was used during the treatment period;
Trial: NCT05743075
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution
Trial: NCT05615987
Drug: Onabotulinumtoxina for Injection
RxNorm normalized name: Onabotulinumtoxina for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200iu/2ml in both groups
Trial: NCT04697186
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bismuth-containing Quadruple Therapygroup: given for 14 days at a dose of amoxicillin 500 mg 2 capsules BID ，clarithromycin 500mg BID ,rabeprazole 10 mg BID and bismuth 110 mg 2 capsules BID
Trial: NCT04367103
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: prophylaxis for hypotension
Trial: NCT05084560
Drug: AWZ1066S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candidate drug to treat lymphatic filariasis by targeting Wolbachia endosymbiont
Trial: NCT05084560
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04536922
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg /day over 1 hour x 2 days.
Trial: NCT04536922
Drug: Pembrolizumab (KEYTRUDA(R))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 2 mg /kg IV over approximately 30 minutes on Days -2, 21, 42, and 63.
Trial: NCT05799495
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05577364
Drug: R-CHOP Protocol
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab: 375mg/m2 iv.drip D1;~Cyclophosphamide: 750mg/m2 iv.drip D1;~Doxorubicin: 50mg/m2 iv.drip D1;~Vincristine: 1.4g/m2 iv D1;~Prednisone: 100mg po D1-5;
Trial: NCT05615194
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume equivalent in infusion over 10 minutes
Trial: NCT06157320
Drug: Shen-Fu
RxNorm normalized name: fu ling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Within 24 hours of sepsis diagnosis, patients received a daily intravenous infusion of 100 ml of Shenfu Injection for a continuous duration of 7 days.
Trial: NCT06157320
Drug: Norepinephrine (NE)，antibiotics，fluid resuscitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: empirical antimicrobial treatment (which is promptly administered after microbial tests), fluid (crystalloids) replacement (to be established according to fluid tolerance and fluid responsiveness), and vasoactive agents (e.g., norepinephrine (NE)), which are employed to maintain mean arterial pressure above 65 mmHg and reduce the risk of fluid overload
Trial: NCT05285124
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants assigned to the melatonin group were given a 3-mg fast-release oral dose of melatonin administered at approximately 21:00
Trial: NCT05133713
Drug: Systemic anticoagulation
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative therapy
Trial: NCT06343038
Drug: Injection, 161Tb-SibuDAB,1GBq
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection via peripheral venous catheter of \~1GBq 161Tb-SibuDAB (\~200 μg / \~125 nM) in saline
Trial: NCT06343038
Drug: Injection, 177Lu-PSMA-I&T, 1GBq
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection via peripheral venous catheter of \~1GBq 161Tb-SibuDAB (\~100 μg / \~65 nM) in saline
Trial: NCT06343038
Drug: Injection, 161Tb-SibuDAB, Dose Escalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection via peripheral venous catheter of 161Tb-SibuDAB in saline. The intervention comprises 4 cycles at 6-week intervals.~The 161Tb-SibuDAB entry activity will be calculated based on dosimetry and toxicity data from the first 3 patients in Phase Ia of the study.~The escalated or de-escalated 161Tb-SibuDAB activity for the subsequent 3-patient cohorts will be determined based on the clinical and biochemical safety information and on organ dosimetry results of the entry/previous cohort. Up to 4 escalation or de-escalation steps will be performed.
Trial: NCT06255067
Drug: Minocycline hydrochloride with noisome carrier
RxNorm normalized name: Minocycline Hydrochloride
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patient will receive Non-surgical debridement followed by injection of local delivery drug in the deepest pocket site, This will be done one day, three days, seven days and fourteen days
Trial: NCT06255067
Drug: Minocycline Hydrochloride only
RxNorm normalized name: Minocycline Hydrochloride
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patient will receive Non-surgical debridement followed by injection of local delivery drug in the deepest pocket site, This will be done one day, three days, seven days and fourteen days
Trial: NCT06606067
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet daily
Trial: NCT04848714
Drug: ANAWIDOW [antivenin latrodectus (black widow) equine immune F(ab)2] lyophilized powder for solution 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antivenin latrodectus (black widow) equine immune F(ab)2\] lyophilized powder for solution 10 mL for intravenous use \[parenteral formulation\]; hence, a single-dose fasting pharmacokinetic study is planned.
Trial: NCT06299982
Drug: 608 Q2W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 608 160 mg at week 0 + 80 mg Q2W (5 cycles)
Trial: NCT06299982
Drug: 608 Q4W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 608 160 mg Q4W (3 cycles)
Trial: NCT05528367
Drug: Nab-PTX,S-1,Tirelizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1:BSA \<=1.25 m2 ,80 mg daily; 1.25 m2 \<BSA \<1.5 m2,100 mg daily; BSA\>=1.5 m2 ,120 mg daily.~Nab-PTX:130mg/m2,d1，8，q3w；100mg qw(during radiation) Tirelizumab：200mg d1 q3w.
Trial: NCT05268744
Drug: Micronutrient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will take micronutrient supplement daily for 8 weeks
Trial: NCT05753566
Drug: Androgen deprivation therapy (ADT)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT), the ADT used by each subject will be determined by the investigator, and the dose and frequency of administration will be consistent with the prescription information
Trial: NCT04857437
Drug: PF-07202954 Single Dose
RxNorm normalized name: Influenza, high-dose, quadrivalent, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10, 30, 100, 300, 600, 900, 1200 milligrams (mg)
Trial: NCT04857437
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT05077462
Drug: C52R1M Tab. and C52R2 Tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose C52R1M(FDC, Valsartan/Amlodipine) 160/5 mg tablet and C52R2(Chlorthalidone) 25 mg tablet taken together
Trial: NCT05077462
Drug: AJU-C52H
RxNorm normalized name: AJUGA REPTANS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose AJU-C52(Valsartan/Amlodipine/Chlorthalidone) 160/5/25 mg FDC tablet
Trial: NCT04562597
Drug: Dose Response Curve Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 participants will be randomized to the placebo group to estimate the dose response curve and to identify the optimal dose.
Trial: NCT04562597
Drug: Dose Response Curve N-acetylcysteine 50 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 participants will be randomized to the N-acetylcysteine 50 mg/kg group to estimate the dose response curve and to identify the optimal dose.
Trial: NCT04562597
Drug: Dose Response Curve N-acetylcysteine 100 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 participants will be randomized to the N-acetylcysteine 100 mg/kg group to estimate the dose response curve and to identify the optimal dose.